Drugs.com - Clinical Trials

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for people living with genetically driven diseases, today...

Feb 9, 2025 - 21:44
 0
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for people living with genetically driven diseases, today...
Read More

Tags:

Previous Article

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Pha...

Next Article

Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia

Related Posts

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune HPV in HPV16-Positive Head and Neck Cancer

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Tr...

Mar 9, 2025  0

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Immunovant Announces Positive Results for Batoclimab My...

Mar 19, 2025  0

Orforglipron Demonstrated Statistically Significant Efficacy Results and a Safety Profile Consistent with Injectable GLP-1 Medicines in Successful Phase 3 Trial

Orforglipron Demonstrated Statistically Significant Eff...

Apr 18, 2025  0